featured-image

Maddie Meyer/Getty Images News Moderna ( NASDAQ: MRNA ) announced Thursday that its next-generation COVID-19 vaccine candidate, mRNA-1283, achieved the primary efficacy endpoint in a Phase 3 trial consistent with previously disclosed interim data. Citing data from more than 11,000 individuals aged 12 years and older, the Cambridge, Massachusetts-based biotech said mRNA-1283's performance against COVID was at least similar (non-inferior) to that of its FDA-approved vaccine, mRNA-1273 (Spikevax). Higher efficacy rates were seen in those aged 18 and older with a consistent trend also observed in a group comprising adults aged 65 and older.

Both vaccines were found to have a similar safety profile. Unlike Spikevax, mRNA-1283 is a refrigeration-stable vaccine formulation with a longer shelf life and storage advantages. Moderna ( MRNA ) announced interim immunogenicity data from the study in March after mRNA-1283 reached the study's primary goals.



The company said it would start discussions with regulators to determine the next steps. More on Moderna Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Moderna, Inc.

(MRNA) Jefferies 2024 Global Healthcare Conference (Transcript) Moderna, Inc. (MRNA) Moderna Oncology Investor Event (Transcript) Moderna’s COVID/flu combo vaccine succeeds in late-stage trial FDA selects JN.1 variant for next COVID vaccine campaign.

Back to Health Page